Versican, a cardiac fibroblast-derived extracellular matrix component, promoted cardiomyocyte proliferation, reduced fibrosis, and improved cardiac function after myocardial infarction in mice.
Does versican promote cardiomyocyte proliferation and cardiac repair in models of myocardial injury?
Versican acts as a pro-proliferative proteoglycan that promotes cardiomyocyte proliferation and cardiac repair via integrin β1 signaling, highlighting its potential as a therapeutic factor for ischemic heart diseases.
BACKGROUND: The adult mammalian heart is incapable of regeneration, whereas a transient regenerative capacity is maintained in the neonatal heart, primarily through the proliferation of preexisting cardiomyocytes. Neonatal heart regeneration after myocardial injury is accompanied by an expansion of cardiac fibroblasts and compositional changes in the extracellular matrix. Whether and how these changes influence cardiomyocyte proliferation and heart regeneration remains to be investigated. METHODS: We used apical resection and myocardial infarction surgical models in neonatal and adult mice to investigate extracellular matrix components involved in heart regeneration after injury. Single-cell RNA sequencing and liquid chromatography–mass spectrometry analyses were used for versican identification. Cardiac fibroblast–specific Vcan deletion was achieved using the mouse strains Col1a2-2A-CreER and Vcan fl/fl . Molecular signaling pathways related to the effects of versican were assessed through Western blot, immunostaining, and quantitative reverse transcription polymerase chain reaction. Cardiac fibrosis and heart function were evaluated by Masson trichrome staining and echocardiography, respectively. RESULTS: Versican, a cardiac fibroblast–derived extracellular matrix component, was upregulated after neonatal myocardial injury and promoted cardiomyocyte proliferation. Conditional knockout of Vcan in cardiac fibroblasts decreased cardiomyocyte proliferation and impaired neonatal heart regeneration. In adult mice, intramyocardial injection of versican after myocardial infarction enhanced cardiomyocyte proliferation, reduced fibrosis, and improved cardiac function. Furthermore, versican augmented the proliferation of human induced pluripotent stem cell–derived cardiomyocytes. Mechanistically, versican activated integrin β1 and downstream signaling molecules, including ERK1/2 and Akt, thereby promoting cardiomyocyte proliferation and cardiac repair. CONCLUSIONS: Our study identifies versican as a cardiac fibroblast–derived pro-proliferative proteoglycan and clarifies the role of versican in promoting adult cardiac repair. These findings highlight its potential as a therapeutic factor for ischemic heart diseases.
Feng et al. (Fri,) conducted a other in Myocardial injury / Myocardial infarction. Versican was evaluated on Cardiomyocyte proliferation and cardiac repair. Versican, a cardiac fibroblast-derived extracellular matrix component, promoted cardiomyocyte proliferation, reduced fibrosis, and improved cardiac function after myocardial infarction in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: